Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer Drug Rigosertib
- The companies collaborated to identify biomarkers of response to Onconova’s rigosertib using Pangea Biomed’s algorithmic platform ENLIGHT. Under the research collaboration, Onconova holds all rights to rigosertib & will own intellectual property
- The collaboration was based on the clinical data which showed an anti-cancer activity of rigosertib with checkpoint inhibition for KRAS-mutated NSCLC & rigosertib monotx. for advanced SCC. Onconova also informs a precision medicine approach toward rigosertib’s evaluation in new indications
- Rigosertib is being studied in multiple investigator-sponsored studies, incl. a dose-escalation & expansion P-I/IIa study in combination with nivolumab for KRAS+ NSCLC & in P-II program for advanced RDEB-associated SCC
Ref: Globenewswire | Image: Onconova Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.